Winning a won game: Caffeine panacea for obesity syndemic

Current Neuropharmacology

Volumn 8, Issue 2, 2010, Pages 149-160

  Myslobodsky, M ^a,b   Eldan, A ^c  

^a HOWARD UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c Wide MedLtd ^*  (Israel)

Author keywords

Caffeine targets; Networks; Obesity; Polypharmacy; Reactive oxygen species

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; BEVACIZUMAB; CAFFEINE; CASOPITANT; CISPLATIN; CJ 012 255; CJ O12 255; DEXAMETHASONE; EPHEDRINE; GROWTH HORMONE RELEASING FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LEVODOPA; MELATONIN; NITRIC OXIDE; PLACEBO; PREPROTACHYKININ; REACTIVE OXYGEN METABOLITE; RYANODINE RECEPTOR; TACHYKININ PRECURSOR 1; TACHYKININ RECEPTOR ANTAGONIST; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANOREXIA; ANTICONVULSANT ACTIVITY; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ELECTROENCEPHALOGRAPHY; EPILEPSY; FOOD INTAKE; HUMAN; INSOMNIA; NONHUMAN; OBESITY; OSTEOSARCOMA; PARKINSONISM; PROTEIN FUNCTION; PSORIASIS VULGARIS; SIGNAL TRANSDUCTION; SLEEP APNEA SYNDROME; WEIGHT REDUCTION;

EID: 77953673096     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015910791233213     Document Type: Article

References (157)

1. Haslam, D., Sattar, N., Lean, M. (2006) Obesity-time to wake up. BMJ, 333, 640-642.
2. Flier, J,S., Elmquist, J.K. (2004) A Good Night's Sleep: Future Antidote to the Obesity Epidemic? Ann. Intern. Med., 141, 885-886.
3. Bass, J., Turek, F.W. (2005) Sleepless in America A Pathway to Obesity and the Metabolic Syndrome? Arch. Intern. Med., 165, 1516.
4. Tjepkema, M. (2005) Insomnia. Health Rep., 17, 9-25.
5. Vorona, R.D., Winn, M.P., Babineau, T.W., Eng, B.P., Feldman, H.R., Ware J.C. (2005) Overweight and Obese Patients in a Primary Care Population Report Less Sleep Than Patients With a Normal Body Mass Index. Arch. Intern. Med., 165, 25-23.
6. Terzano, M.G., Rossi, M., Palomba, V., Smerieri, A., Parrino, L. New drugs for insomnia: comparative tolerability of zopiclone, Zolpidem and zaleplon. Drug Saf., 26, 261-282.
7. Nilsson. P.M., Roost, M., Engstrom, G., Hedblad, B., Berglund, G. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care, 27, 2464-2469.
8. Penev, P. (2007) Sleep deprivation and energy metabolism: to sleep, perchance to eat? Curr. Opin. Endocrinol. Diabetes Obes., 14, 374-381.
9. Patel, S.R., Blackwell, T., Redline, S., Ancoli-Israel, S., Cauley, J.A., Hillier, T.A., Lewis, C.E., Orwoll, E.S., Stefanick, M.L., Taylor, B.C., Yaffe, K., Stone, K.L. Osteoporotic Fractures in Men Research Group; Study of Osteoporotic Fractures Research Group. (2008) The association between sleep duration and obesity in older adults. Int. J. Obes., 32, 1825-1834.
10. Blundell, J.E. (2006) Perspective on the central control of appetite. Obesity (Silver Spring), 14 (Suppl 4), 160S-163S.
11. Nielsch, U., Schafer, S., Wild, H., Busch, A. (2007) One target-multiple indications: a call for an integrated common mechanisms strategy. Drug Discov. Today, 12, 1025-1031.
12. Connor, S. (2003) Glaxo chief: Our drugs do not work on most patients. Independent, 8, 1.
13. Crawford, C. (2000) Evolutionary psychology: counting babies or studying information-processing mechanisms. Ann. N. Y. Acad. Sci., 907, 21-38.
14. Huang, C., Dumanovsky, T., Silver, L.D., Nonas, C., Bassett, M.T. (2009) Calories from beverages purchased at 2 major coffee chains in New York City, 2007. Prev. Chronic Dis., 6, A118.
15. Fredholm, B.B., Bättig, K., Holmén, J., Nehlig, A., Zvartau, E. (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev., 51, 83-126.
16. Landolt, H.P. (2008) Sleep homeostasis: A role for adenosine in humans? Biochem. Pharmacol., 75, 2070-2079.
17. Janson, C., Lindberg, E. Gislason, T., Elmasry, A., Boman, G. (2001) Insomnia in men - A 10-year prospective population based study. Sleep, 24, 425-430
18. Hasler, G., Buysse, D.J., Klaghofer, R., Gamma, A., Ajdacic, V., Eich, D., Rössler, W., Angs, J. (2004) The association between short sleep duration and obesity in young adults: a 13-year prospective study. Sleep, 27, 661-666.
19. Lauderdale, D.S., Knutson, K.L., Rathouz, P.J., Yan, L.L., Hulley, S.B., Liu, K. (2009) Cross-sectional and Longitudinal Associations Between Objectively Measured Sleep Duration and Body Mass Index: The CARDIA Sleep Study. Am. J. Epidemiol., 170, 805-13.
20. Snyder, S.H., Sklar, P. (1984) Behavioral and molecular actions of caffeine: focus on adenosine. J. Psychiatr. Res., 18, 91-106.
21. Daly, J.W. (2000) Alkylxanthines as research tools. J. Auton. Nerv. Syst., 81, 44-52.
22. Daly, J.M. (2007) Caffeine analogs: biomedical impact Life Sci., 64, 2153 - 2169.
23. Calvano, S.E., Xiao, W., Richards, D.R., Felciano, R.M., Baker, H.V, Cho, R.J., Chen, R.O, Brownstein, B.H., Cobb, J.P., Tschoeke S.K, Miller-Graziano, C., Moldawer, L.L., Mindrinos, M.N., Davis, R.W., Tompkins, R.G., Lowry, S.F. (2005) A network-based analysis of systemic inflammation in humans. Nature, 437, 1032-1037.
24. Myslobodsky, M. (2009) The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis. Curr. Drug Targets, 10, 1009-1020.
25. Sullivan, S.S., Guilleminault, C. (2009) Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin. Emerg. Drugs, 14, 411-422.
26. Karagiannides, I., Torres, D., Tseng, Y.H., Bowe, C., Carvalho, E., Espinoza, D., Pothoulkais, C., Kokkotou, E. (2008) Substance P as a novel anti-obesity target. Gastroenterology, 134, 747-755.
27. Eichling. P.S., Sahni. J. (2005) Menopause related sleep disorders. J. Clin. Sleep Med., 15, 291-300.
28. Zhang, G.W. L., Liu, H., Zhang, J. (2004) Substance P promotes sleep in the ventrolateral preoptic area of rats. Brain Res., 1028, 225-232.
29. Dray, C., Daviaud, D., Guigné, C., Valet, P., Castan-Laurell, I. (2007) Caffeine reduces TNFalpha up-regulation in human adipose tissue primary culture. J. Physiol. Biochem., 63, 329-336.
30. Strandberg, L., Mellström, D., Ljunggren, O., Grundberg, E., Karlsson, M.K., Holmberg, A.H., Orwoll, E.S., Eriksson, A.L., Svedberg, J., Bengtsson, M., Ohlsson, C., Jansson, J.O. (2008) IL6 and IL1B polymorphisms are associated with fat mass in older men: the MrOS Study Sweden. Obesity (Silver Spring), 16, 710-713.
31. Horrigan, L.A., Kelly, J.P., Connor, T.J. (2004) Caffeine suppresses TNF-[alpha] production via activation of the cyclic AMP/protein kinase A pathway. Int. Immunopharmacol., 4,1409-1417.
32. Chavez-Valdez, R., Wills-Karp, M., Ahlawat, R., Cristofalo, E.A., Nathan, A., Gauda, E.B. (2009) Caffeine modulates TNF-alpha production by cord blood monocytes: the role of adenosine receptors. Pediatr. Res., 65, 203-208.
33. Krueger, J.M., Rector, D.M., Roy, S., Van Dongen, H.P., Belenky, G., Panksepp, J. (2008) Sleep as a fundamental property of neuronal assemblies. Nat. Rev. Neurosci., 9, 910-919.
34. Szentirmai, E., Yasuda, T., Taishi, P., Wang, M., Churchill, L., Bohnet, S., Magrath, P., Kacsoh B, Jimenez, L., Krueger. J.M. Growth hormone-releasing hormone: cerebral cortical sleep-related EEG actions and expression. Am. J. Physiol. Regul. Integr. Comp. Physiol., 293, R922-930.
35. Liu, Z.W., Gao, X.B. (2007) Adenosine inhibits activity of hypocretin/orexin neurons by the A1 receptor in the lateral hypothalamus: a possible sleep-promoting effect. J. Neurophysiol., 9, 837-848.
36. Casadó, V., Cortés, A., Mallol, J., Pérez-Capote, K., Ferré, S., Lluis, C., Franco, R., Canela, E.I. (2009) GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers? Pharmacol. Ther., 124, 248-257.
37. Ferre, S., Ciruela, F., Borycz, J., Solinas, M., Quarta, D., Antoniou, K., Quiroz, C., Justinova, Z., Lluis, C., Franco, R., Goldberg, S.R. Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front. Biosci., 13, 2391-2399.
38. Naguib, M., Gottumukkala,V., P.A. Goldstein. (2007) Melatonin and anesthesia: a clinical perspective. J. Pineal. Res., 42, 12-21.
39. Härtter, S., Nordmark, A., Rose, D.M., Bertilsson, L., Tybring, G., Laine, K. (2003) Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br. J. Clin. Pharmacol., 56, 679-682.
40. Tan, D., Manchester, L.C., Terron, M.P., Flores, L.J., Reiter, R.J. (2007) One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res., 42, 28-42.
41. Ursing, C., Wikner, J., Brismar, K., Rojdmark, S. (2003) Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450(CYP)1A2. J. Endocrinol. Invest., 26, 403-406.
42. Song, Y.M., Chen, M.D. (2009) Effects of melatonin administration on plasma leptin concentration and adipose tissue leptin secretion in mice. Acta Biol. Hung, 60, 399-407.
43. Huang, Q., Timofeeva, E., Richard, D. (2006) Regulation of corticotropin-releasing factor and its types 1 and 2 receptors by leptin in rats subjected to treadmill running-induced stress. J. Endocrinol., 191, 179-188.
44. Alonso-Vale,M.I.C., Andreotti, S., Peres, S.B., Anhe, G.F., das Neves Borges-Silva, C., Neto, J.C., Lima, F.B. (2005) Melatonin enhances leptin expression by rat adipocytes in the presence of insulin. Am. J. Physiol. Endocrinol. Metab., 288, E805-812.
45. Wolden-Hanson, T., Mitton, D.R., McCants, R.L., Yellon, S. M., Wilkinson, C. W., Matsumoto, A. M., Rasmussen, D.D. (2000) Daily Melatonin Administration to Middle-Aged Male Rats Suppresses Body Weight, Intraabdominal Adiposity, and Plasma Leptin and Insulin Independent of Food Intake and Total Body Fat. Endocrinology, 141, 487-497.
46. Prunet-Marcassus, B., Desbazeille, M., Bross, A., Louche, K., Delagrange, P., Renard, P., Casteilla, L., Penicaud, L. (2003) Melatonin Reduces Body Weight Gain in Sprague Dawley Rats with Diet-Induced Obesity. Endocrinology, 144, 5347-5352.
47. She, M., Deng, X., Guo, Z., Laudon, M., Hu, Z., Liao, D., Hu, X., Luo, Y., Shen, Q., Su, Z., Yin, W. (2009) NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol. Res., 59, 248-253.
48. Simon, C., Gronfier, C., Schlienger, J.L., Brandenberger, G. (1998) Circadian and Ultradian Variations of Leptin in Normal Man under Continuous Enteral Nutrition: Relationship to Sleep and Body Temperature. J. Clin. Endocrinol. Metab., 83, 1893-1899.
49. Sinton, C.M., Fitch, T.E., and Gershenfeld, H.K. (1999) The effects of leptin on REM sleep and slow wave delta in rats are reversed by food deprivation. J. Sleep Res., 8, 197-203.
50. Laposky, A.D., Shelton, J., Bass, J, Dugovic C, Perrino N, Turek FW. (2006) Altered sleep regulation in leptin-deficient mice. Am J Physiol. Regul. Integr. Comp. Physiol., 290, R894-903.
51. Qin, L., Li, J., Wang, Y., Wang, J., Xu, J.Y., and Kaneko, T. (2003) The effects of nocturnal life on endocrine circadian patterns in healthy adults. Life Sci., 73, 2467-2475.
52. Bogdan, A., Bouchareb, B., Touitou, Y. (2001) Ramadan fasting alters endocrine and neuroendocrine circadian patterns. Meal-time as a synchronizer in humans? Life Sci., 68, 1607-1615.
53. Bogdan, A., Bouchareb. B., Touitou. Y. (2005) Response of circulating leptin to Ramadan daytime fasting: a circadian study. Br. J. Nutr., 93, 515-518.
54. Goel, N., Stunkard, A.J., Rogers, N.L.,Van Dongen HP, Allison KC, O'Reardon JP, Ahima RS, Cummings DE, Heo M, Dinges DF. (2009) Circadian Rhythm Profiles in Women with Night Eating Syndrome. J. Biol. Rhythms 24, 85-94.
55. Motivala, S.J., Tomiyama, A.J., Ziegler, M., Khandrika, S., Irwin, M.R. (2009) Nocturnal levels of ghrelin and leptin and sleep in chronic insomnia. Psychoneuroendocrinology, 34, 540-545.
56. Arnardottir, E.S., Mackiewicz, M., Gislason, T., Teff, K.L., Pack, A.I. (2009) Molecular signatures of obstructive sleep apnea in adults: a review and perspective. Sleep, 32, 447-470.
57. Skurk, T., Alberti-Huber, C., Herder, C., Hauner, H. (2007) Relationship between Adipocyte Size and Adipokine Expression and Secretion. J. Clin. Endocrinol. Metab., 92, 1023-1033.
58. Danforth, E.J. (2000) Failure of adipocyte differentiation causes type II diabetes mellitus? Nat. Genet., 26, 13.
59. Hemmrich, K., Gummersbach, C., Pallua, N., Luckhaus, C., Fehsel, K. (2006) Clozapine enhances differentiation of adipocyte progenitor cells. Mol. Psychiatry, 11, 980-981.
60. Gavrilova, O., Marcus-Samuels, B., Graham, D., Kim, J.K., Shulman, G.I., Castle, A.L., Vinson, C., Eckhaus, M., Reitman, M.L. (2000) Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest., 105, 271-278.
61. Avram, M.M., Avram, A.S., James, W.D. (2007) Subcutaneous fat in normal and diseased states: 3. Adipogenesis: From stem cell to fat cell. J. Am. Acad. Dermatol., 56, 472-492.
62. Nishimura, S., Manabe, I., Nagasaki, M., Hosoya, Y., Yamashita, H., Fujita, H., Ohsugi, M., Tobe, K., Kadowaki, T., Nagai, R., Sugiura, S. (2007) Adipogenesis in Obesity Requires Close Interplay Between Differentiating Adipocytes, Stromal Cells, and Blood Vessels. Diabetes, 56, 1517-1526.
63. Wellen, K.E., Hotamisligil, G.S. (2005) Inflammation, stress, and diabetes. J. Clin. Invest., 115, 1111-1119.
64. Subauste, A.R., Burant, C.F. (2007) Role of FoxO1 in FFA-induced oxidative stress in adipocytes. Am. J.Physiol. Endocrinol. Metab., 293, E159-164.
65. Kamat, J.P., Boloor, K. K. Devasagayam, T. P. Jayashree, B. Kesavan, P. C. (2000) Differential modification by caffeine of oxygen-dependent and independent effects of gamma-irradiation on rat liver mitochondria. Int. J. Radiat. Biol., 76, 1281-1288.
66. Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J., Holash, J. (2000) Vascular-specific growth factors and blood vessel formation. Nature, 407, 242-248.
67. Fredholm, B.B. (2007) Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ., 14, 1315-1323.
68. Ledoux, S., Queguiner, I., Msika,S., Calderari, S., Rufat, P., Gasc, J.M., Corvol, P., Larger, E. (2008) Angiogenesis Associated With Visceral and Subcutaneous Adipose Tissue in Severe Human Obesity. Diabetes, 57, 3247-3257.
69. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285, 1182-1186.
70. Jacobson, K.A. (2009) Introduction to Adenosine Receptors as Therapeutic Targets. Handb. Exp. Pharmacol., pp. 1-24.
71. Stone, T.W., Ceruti, S., Abbracchio, M.P. (2009) Adenosine Receptors and Neurological Disease: Neuroprotection and Neuro-degeneration. Adenosine Recept. Health Dis., pp. 535-587.
72. Cohen. M.V., Downey, J.M. (2008) Adenosine: trigger and mediator of cardioprotection. Basic Res. Cardiol., 103, 203-215.
73. Taylor, C.T. (2008) Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem. J., 409, 19-26.
74. Dvorak, H.F. (2005) Angiogenesis: update 2005. J. Thromb. Haemost., 3, 1835-1842.
75. Widberg, C.H., Newell, F.S., Bachmann, A.W., Ramnoruth, S.N., Spelta, M.C., Whitehead, J.P., Hutley, L.J., Prins, J.B. (2009) Fibroblast growth factor receptor 1 is a key regulator of early adipogenic events in human preadipocytes. Am J Physiol. Endocrinol. Metab., 296, E121-131.
76. Nagy, J.A., Dvorak, A.M., Dvorak, H.F. (2007) VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol., 2, 251-275.
77. Gomez-Ambrosi, J., Catalan, V., Rodriguez, A, Ramirez, B., Silva, C., Gil, M.J., Salvador, J., Fruhbeck, G. (2009) Involvement of serum vascular endothelial growth factor family members in the development of obesity in mice and humans. J. Nutr. Biochem., [Epub ahead of print].
78. Zhang, Q.X., Magovern, C.J., Mack, C.A., Budenbender, K,T., Ko, W., Rosengart, T.K. (1997) Vascular Endothelial Growth Factor Is the Major Angiogenic Factor in Omentum: Mechanism of the Omentum-Mediated Angiogenesis. J. Surg. Res., 67, 147-154.
79. Pastorino, F., Di Paolo, D., Loi, M., Becherini, P., Caffa, I., Zorzoli, A., Marimpietri, D., Carosio, R., Perri, P., Montaldo, P. G., Brignole, C., Pagnan, G., Ribatti, D., Allen, T. M., Ponzoni, M. (2009) Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model. Curr. Drug Targets, 10, 1021-1027.
80. Gurevich, F., Perazella, M.A. (2009) Renal effects of anti-angiogenesis therapy: update for the internist. Am. J. Med., 122, 322-328.
81. Feihl, F., Liaudet, L., Waeber, B., Levy, B.I. (2006) Hypertension, a disease of the microcirculation? Hypertension, 48, 1012-1017.
82. Feihl, F., Liaudet, L., Levy, B.I., Waeber, B. (2008) Hypertension and microvascular remodelling. Cardiovasc. Res. 22, cvn022.
83. Mourad, J.J., des Guetz, G., Debbabi, H., Levy, B.I. (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann. Oncol., 19(5), 927-34.
84. Kiefer, F.N., Neysari, S., Humar, R., Li, W., Munk, V.C., Battegay, E.J. (2003) Hypertension and angiogenesis. Curr. Pharm. Des., 9, 1733-1744.
85. Pasarica, M., Sereda, O. R. Redman, L. M. Albarado, D. C. Hymel, D. T. Roan, L., Rood, J.C., Burk, D.H., Smith, S.R. (2009) Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes, 58, 718-725.
86. Sabisz, M., Skladanowski, A. (2008) Modulation of cellular response to anticancer treatment by caffeine: inhibition of cell cycle checkpoints, DNA repair and more. Curr. Pharm. Biotechnol., 9, 325-336.
87. Liao, J.Y. G.Y., Park, E. S., Meng, X., Sun, Y,. Jia, D., Seril, D. N.,Yang, C.S. (2004) Inhibition of lung carcinogenesis and effects on angiogenesis and apoptosis in A/J mice by oral administration of green tea. Nutr. Cancer, 48, 44-53.
88. Ryzhov, S., McCaleb, J. L., Goldstein, A. E., Biaggioni, I., Feoktistov, I. (2007) Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia. J. Pharmacol. Exp. Ther., 320, 565-572.
89. Zhao, J., van Helden, D.F. (2003) ET-1-associated vasomotion and vasospasm in lymphatic vessels of the guinea-pig mesentery. Br. J. Pharmacol., 140, 1399-1413.
90. Edwards, J.M.A., M. A. Long, X. L. Dick, G. M., Lloyd, P. G., Mokelke, E. A., Sturek, M. (2008) Adenosine A1 receptors in neointimal hyperplasia and in-stent stenosis in Ossabaw miniature swine. Coron. Artery Dis., 19, 27-31.
91. Gunga, H.C., Fries, D., Humpeler, E., Kirsch, K., Boldt, L.E., Koralewski, E., Johannes, B., Klingler, A., Mittermayr, M., Rocker, L., Yaban, B., Behn, C., Jelkmann, W., Schobersberger, W. (2003) Austrian Moderate Altitude Study (AMAS 2000) - fluid shifts, erythropoiesis, and angiogenesis in patients with metabolic syndrome at moderate altitude (congruent with 1700 m). Eur. J. Appl. Physiol., 88, 497-505.
92. Garvey, J.F., Taylor, C.T., McNicholas, W.T. (2009) Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur. Respir. J., 33, 1195-1205.
93. Lavie, L. (2009) Oxidative stress-a unifying paradigm in obstructive sleep apnea and comorbidities. Prog. Cardiovasc. Dis., 51, 303-312.
94. Lavie, P., Lavie, L. (2009) Unexpected survival advantage in elderly people with moderate sleep apnoea. J. Sleep. Res., 18, 397-403.
95. Son, T.G., Camandola, S., Mattson, M.P. (2008) Hormetic Dietary Phytochemicals. Neuro. Mol. Med., 10, 236-246.
96. Calabrese, E.J. (2008) Converging concepts: Adaptive response, preconditioning, and the Yerkes-Dodson Law are manifestations of hormesis. Ageing Res. Rev., 7, 8-20.
97. Nabe, B.L. A., Pankow, W., Kohl, F.W., Lohmann. F.W. (1995) Determinants of circadian blood pressure rhythm and blood pressure variability in obstructive sleep apnoea. J. Sleep Res., 4, 97-101.
98. Tsioufis, C., Syrseloudis, D., Dimitriadis, K, Thomopoulos, C., Tsiachris, D., Pavlidis, P., Selima, M., Kallikazaros, I., Stefanadis, C. (2008) Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension. J. Hum. Hypertens, 22, 501-508.
99. Williams, C.J., Fargnoli, J.L., Hwang, J.J., van Dam, R.M., Blackburn, G.L., Hu, F.B., Mantzoros, C.S. (2008) Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study. Diabetes Care, 31, 504-507.
100. Murphy, P., Ahmed, N., Hassan, H.T. (2002) Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera. Leuk. Res., 26, 1007-1010.
101. Landaw, S.A. (1990) Polycythemia vera and other polycythemic states. Clin. Lab Med., 10, 857-871.
102. Norman, D., Bardwell, W.A., Loredo, J.S., Ancoli-Israel, S., Heaton, R.K., Dimsdale, J.E. (2008) Caffeine intake is independently associated with neuropsychological performance in patients with obstructive sleep apnea. Sleep Breath., 12, 199-205.
103. Yoshimura, H. (2005) The potential of caffeine for functional modification from cortical synapses to neuron networks in the brain. Curr. Neuropharmacol., 3, 309-316.
104. Pietersen, A.N., Lancaster, D.M., Patel, N., Hamilton, J.B., Vreugdenhil, M. (2009) Modulation of gamma oscillations by endogenous adenosine through A1 and A2A receptors in the mouse hippocampus. Neuropharmacology, 56, 481-492.
105. Kidd, P.M. (2008) Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern. Med. Rev., 13, 85-115.
106. Spinetta, M.J., Woodlee, M.T., Feinberg, L.M. Stroud, C., Schallert, K., Cormack, L.K., Schallert, T. (2008) Alcohol-induced retrograde memory impairment in rats: prevention by caffeine. Psychopharmacology (Berl), 201, 361-371.
107. Knoblovits P, Costanzo, P. R. Rey Valzacchi, G. J. Gueglio, M. G. Layus, A. O. Kozak, A. E. Balzaretti, M. I., Litwak LE. (2009) Erectile Dysfunction, Obesity, Insulin Resistance, and Their Relationship with Testosterone Levels in Eugonadal Patients in an Andrology Clinic Setting. J. Androl., [Epub ahead of print].
108. Yang, R., Wang, J., Chen, Y., Sun, Z., Wang, R., Dai, Y. (2008) Effect of Caffeine on Erectile Function via Up-Regulating Cavernous Cyclic Guanosine Monophosphate in Diabetic Rats. J. Androl., 29, 586-591.
109. Colas C, Cebrian-Perez JA, Muino-Blanco T. (2009) Caffeine induces ram sperm hyperactivation independent of cAMP-dependent protein kinase. Int. J. Androl., [Epub ahead of print].
110. Hammoud AO, Wilde, N. Gibson, M., Parks A, Carrell DT, Meikle AW. (2008) Male obesity and alteration in sperm parameters. Fertil. Steril., 90, 2222-2225.
111. Lee HS, Kim, K. R. Chung, W. H. Cho, Y. S. Hong, S. H. (2008) Early sensorineural hearing loss in ob/ob mouse, an animal model of type 2 diabetes. Clin. Exp. Otorhinolaryngol., 1, 211-216.
112. Hong, B.N., Yi, T. H., Park, R., Kim, S. Y., Kang, T. H. (2008) Coffee improves auditory neuropathy in diabetic mice. Neurosci. Lett., 441, 302-306.
113. Meier, M., Sheth, P.B. (2009) Clinical spectrum and severity of psoriasis. Curr Probl. Dermatol., 38, 1-20.
114. Vali, A., Asilian, A., Khalesi, E., Khoddami, L., Shahtalebi, M., Mohammady M. (2005) Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris. J. Dermatolog. Treat., 16, 234-237.
115. Collins, C., Laird, R.I., Richards PT, Starmer GA, Weyrauch S. (1979) Aspirin-caffeine interaction in the rat. J. Pharm. Pharmacol., 31, 611-614.
116. Martin-Schild, S., Hallevi, H., Shaltoni, H., Barreto, A.D., Gonzales, N.R., Aronowski, J., Savitz, S.I., Grotta, J.C. (2009) Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermia. J. Stroke Cerebrovasc. Dis., 18, 86-96.
117. Yu, L., Schwarzschild, M.A., Chen, J.F. (2006) Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice. Neurosci. Lett., 393, 31-35.
118. Astrup, A., Breum, L., Toubro, S., Hein, P. and Quaade, F. (1992) The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int. J. Obes. Relat. Metab. Disord., 16, 269-277.
119. Blanck, H., Serdula, M. K. Gillespie, C. Galuska, D. A. Sharpe, P. A. Conway, J. M. Khan, L. K. Ainsworth, B. E. (2007) Use of nonprescription dietary supplements for weight loss is common among Americans. J. Am. Diet. Assoc., 107, 441-447.
120. Hackman, R., Havel, P.J., Schwartz, H.J., Rutledge, J.C., Watnik, M.R., Noceti, E.M., Stohs, S.J., Stern, J.S., Keen, C.L. (2006) Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. Int. J. Obes. (Lond), 30, 1545-1556.
121. Greenway, F.L., Bray, G.A. (2008) Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr. Pract., 14, 697-703.
122. Jessen. A., Buemann, B., Toubro, S., Skovgaard, I.M., Astrup, A. (2005) The appetite-suppressant effect of nicotine is enhanced by caffeine. Diabetes Obes. Metab., 7, 327-333.
123. Bray, G.A. (2000) Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications. Int. J. Obes. Relat. Metab. Disord., 24 Suppl 2, S8-17.
124. Yeomans, M.R., Mobini, S., Chambers, L. (2007) Additive effects of flavour-caffeine and flavour-flavour pairings on liking for the smell and flavour of a novel drink. Physiol. Behav., 92, 831-839.
125. Sawynok, J. (1995) Pharmacological rationale for the clinical use of caffeine. Drugs, 49, 37-50
126. Sawynok, J. (1998) Adenosine receptor activation and nociception. Eur. J. Pharmacol., 347,1-11.
127. Kawahara, M., Takahashi, Y. Takazawa, K. Tsuchiya, H. Tomita, K. Yokogawa, K. Miyamoto, K. (2008) Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas. Anticancer Res., 28, 1681-1685.
128. Hayashi, K., Tsuchiya, H. Yamamoto, N. Shirai, T. Yamauchi, K., Takeuchi, A., Kawahara, M., Miyamoto, K., Tomita, K. (2009) Impact of serum caffeine monitoring on adverse effects and chemotherapeutic responses to caffeine-potentiated chemotherapy for osteosarcoma. J. Orthop. Sci., 14, 253-258
129. Yang, H., Rouse, J., Lukes, L., Lancaster, M., Veenstra, T., Zhou, M., Shi, Y, Park, Y.G., Hunter, K. (2004) Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin. Exp. Metastasis, 21, 719-735.
130. Hu, G., Jousilahti, P., Nissinen, A., Bidel, S., Antikainen, R., Tuomilehto, J. (2007) Coffee consumption and the incidence of antihypertensive drug treatment in Finnish men and women. Am. J. Clin. Nutr., 86, 457-464.
131. Riksen, N.P., Rongen, G.A., Smits, P. (2009) Acute and long-term cardiovascular effects of coffee: implications for coronary heart disease. Pharmacol. Ther., 121, 185-191.
132. Cornelis, M.C., El-Sohemy, A., Campos, H. (2004) Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J. Med. Genet., 41, 758-762.
133. Stafford RS. (2008) Regulating Off-Label Drug Use - Rethinking the Role of the FDA. N, Engl. J. Med., 358, 1427-1429.
134. Carley, D.W. (2005) Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part II. IDrugs, 8, 310-313.
135. Tobinick EL. (2009) The value of drug repositioning in the current pharmaceutical market. Drug News Perspect., 22, 119-125.
136. Ashburn, T.T., Thor, K.B. (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 3, 673-683.
137. Quinones, M.P, Kaddurah-Daouk R. (2009) Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis., 35, 165-176.
138. Myslobodsk,y M., Coppola, R. (2010) Ingestion-Controlling Network: What's Language Got To Do With It? Rev. Neurosci., 21, 67-81.
139. Hopkins, A.L., Mason, J.S., Overington, J.P. (2006) Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol., 16, 127-136.
140. Astrup, A. (2000) Thermogenic drugs as a strategy for treatment of obesity. Endocrine, 13, 207-212.
141. Chaput, J-P., Tremblay, A. (2006) Current and novel approaches to the drug therapy of obesity. Eur. J. Clin. Pharmacol., 62, 793-803.
142. Myslobodsky, M., Ingraham, L.J. (2009) Managing the Pandemic of Obesity: Siding with the Fox or the Hedgehog? Obes. Facts, 2, 384-392.
143. Singer, M., Clair, S. (2003) Syndemics and public health: reconceptualizing disease in bio-social context. Med. Anthropol. Q. 17, 423-441.
144. Merighi, S., Benini, A., Mirandola, P., Gessi, S., Varani, K., Simioni, C., Leung, E., Maclennan, S., Baraldi, P.G., Borea, P.A. (2007) Caffeine Inhibits Adenosine-Induced Accumulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Interleukin-8 Expression in Hypoxic Human Colon Cancer Cells. Mol. Pharmacol., 72, 395-406.
145. Albensi, B.C., Mattson, M.P. (2000) Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 35, 151-159.
146. Suzawa, M., Takada, I., Yanagisawa, J., Ohtake, F., Ogawa, S., Yamauchi, T., Kadowaki, T., Takeuchi, Y., Shibuya, H., Gotoh, Y., Matsumoto, K., Kato, S. (2003) Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat. Cell Biol., 5, 224-230.
147. Gross, K., Karagiannides, I., Thomou, T., Koon, H. W., Bowe, C., Kim, H., Giorgadze, N., Tchkonia, T., Pirtskhalava, T., Kirkland, J. L., Pothoulakis, C. (2009) Substance P promotes expansion of human mesenteric preadipocytes through proliferative and antiapoptotic pathways. Am. J. Physiol. Gastrointest. Liver Physiol., 296, G1012-1019.
148. Obal, F. Jr., Krueger, J.M. (2003) Biochemical regulation of sleep. Front. Biosci. 8, 520-550.
149. Vondracek, S.F., Hansen, L.B., McDermott, M.T. (2009) Osteoporosis risk in premenopausal women. Pharmacotherapy, 29, 305-317.
150. Haguenauer, D., Welch, V., Shea, B., Tugwell, P., Adachi, J.D., Wells, G. (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int., 11, 727-738.
151. Ohta, M., Cheuk, G., Thomas, K.A, Kamagata-Kiyoura, Y., Wink, C.S., Yazdani, M., Falster, A.U., Simmons, W.B., Nakamoto, T. (1999) Effects of caffeine on the bones of aged, ovariectomized rats. Ann. Nutr. Metab., 43, 52-59.
152. Baethge, C., Tondo, L., Lepri, B., Baldessarini, R. J. (2009) Coffee and cigarette use: association with suicidal acts in 352 Sardinian bipolar disorder patients. Bipolar Disord., 11, 494-503.
153. Silverman, K., Evans, S. M., Strain, E. C., Griffiths, R. R. (1992) Withdrawal syndrome after the double-blind cessation of caffeine consumption. N. Engl. J. Med., 327, 1109-1114.
154. Iacobellis, G., Barbaro, G. (2008) The Double Role of Epicardial Adipose Tissue as Pro- and Anti-inflammatory Organ. Horm. Metab. Res., 40, 442-445.
155. Shi, D., Padgett, W.L., Daly, J.W. (2003) Caffeine Analogs: Effects on Ryanodine-Sensitive Calcium-Release Channels and GABAA Receptors. Cell. Mol. Neurobiol., 23, 331-347.
156. Kostopoulos, G., Veronikis, D.K., Efthimiou, I. (1987) Caffeine blocks absence seizures in the tottering mutant mouse. Epilepsia, 28, 415-420.
157. Tchekalarova, J., Kubová, H., Mares, P. (2009) Postnatal caffeine treatment affects differently two pentylenetetrazol seizure models in rats. Seizure, 18, 463-469.